



# Ocular Drug Delivery Validated Solutions

| November 2025

Part of BioLight Group  **BIOLIGHT**  
Life Sciences Ltd.



# Company Overview



## 360° ophthalmology drug delivery solution

Accessing all parts of the eye

---

Short - and long-term therapies

---

Generic and innovative drugs

## Validated technology platforms

Multiple studies demonstrated high efficacy of each platform

## Diverse pipeline

Nano-carried Cyclosporine – phase I

---

Nano-carried Axitinib – swine models

---

1<sup>st</sup> Gen Latanoprost implant – FIH

## Fast regulatory path

Utilization of ophthalmology - approved components

## Huge market potential

Over \$20B TAM for only the three current indications

## World-renowned team and SAB

Including Profs. Ike Ahmed, Anat Loewenstein, Jeff Goldberg, Avi Domb and Nissim Garti



# Ophthalmology drug delivery. **Enhanced.**

**Two validated platforms** offer high-dose therapy or sustained release drug delivery to the anterior and posterior segments of the eye, **minimizing side effects and maximizing efficacy**



# ocudrip™

Maximizing efficacy and minimizing side effects  
with proprietary nano-droplet technology

# ocudrip™

Rapid, reliable development of high-dose droplets for optimal delivery to various ocular compartments



## Nanometric drops with superior characteristics

Enhanced solubility, permeability, and stability

Tailor-made, patented conformation per drug



## Computational platform for maximum success

Unique models evaluate specific needs and predict success

Advanced algorithms optimize droplet composition

# ocudrip™

Nano-droplets benefit all stakeholders

## Patients

Non-invasive procedure

No discomfort or irritation



## Clinicians

Reliable topical administration

Enhanced efficacy



## Manufacturers

Stable for storage,  
transportation and use


Suitable for generic  
and novel ingredient

Unified delivery technology  
for all parts of the eye




## Mechanism of Action

- Self assembled droplets of 50nm or less – transparent, stable, pH insensitive formulation
- Releases payload upon interaction with the target tissue
- Hydrophilic and hydrophobic molecules can be solubilized separately or in combination



- Enables solubilization of Low>High MW APIs  
Allows for higher concentration of APIs  
(e.g. Cyclosporine 0.5%)



## Molecular Architecture Droplets A Novel Drug Delivery Platform



Enhanced bioavailability enables topical administration of APIs to both anterior and posterior segments.



High solubilization capacity of a wide range of APIs, bypasses traditional limitation of size and polarity.



Well tolerated, preservative free, water-like droplets.



Nano-carried Cyclosporine phase 1 completed

Conjunctival delivery

## Enhanced dosage and reduced side effects

Demonstrated comparable safety while delivering X10 active drug compared to Restasis™

0.5% nano-carried Cyclosporine vs. Restasis™  
(0.05% Cyclosporine)




## Nano-carried Axitinib preclinical swine models completed

### Retinal delivery

### Retinal administration through topical delivery

Topical administration showed comparable efficacy to IVT-injected EYLEA

Laser-induced choroidal neovascularization (CNV) model





ocugrid™

Sub-conjunctival implant platform  
for sustained drug release in chronic conditions

# ocugrid™

Sub-conjunctival interventions are regarded as non-invasive procedures, enabling superior efficacy with minimal complications



## Slow-release degradable implant



Controlled drug release for over 3 months



3.5 mm

Compatible with multiple drugs and conditions



## Sub-conjunctival injector

Maximum proximity to the inner eye without penetration

Easy to use in-office

# ocugrid™

Sub-conjunctival implant benefit all stakeholders

## Patients

Minimal discomfort

"Fire and forget"  
No removal or daily application



## Clinicians

Sustained and stable  
drug release over time

Fewer complications

Improved compliance



## Manufacturers

Supports multiple drug types

Low cost-of-goods

Enables delivery to various  
ocular compartments




## Clinical and advanced preclinical validation

### 1<sup>st</sup> Gen (non degradable)


#### Phase I-IIa slow-release Latanoprost formulation US study completed

Demonstrated excellent safety and comparable efficacy as topical Latanoprost



### 2<sup>nd</sup> Gen (degradable)


#### Preliminary release profiles validation



0.5% w/w loaded latanoprost-arginine at various matrix compositions

#### Rabbit model slow-release Latanoprost formulation completed

Demonstrated excellent safety profile



- No unexpected adverse events with OcuGrid's sub-conjunctival injector
- Study arms: 2<sup>nd</sup>-gen implant with and without Latanoprost
- 16 week follow up

# Ocuvia's Unique Offering



## 360° ophthalmology drug delivery offering

Delivery of generic and novel drugs

Low-dose sustained release  
or high-dose transient delivery

Solutions to various  
ocular compartments



## Simplified delivery

Only ophthalmology-approved materials

Alleviated treatment burden

Treatment in  
outpatient / ambulatory setting



# Leading KOLs



**Dr. Joe Tauber**  
CMO, multiple  
ophthalmology  
companies



**Dr. Ron Neuman**  
CMO, multiple  
ophthalmology  
companies



**Prof. David Zadok**  
Shaare Zedek  
Medical Center,  
Jerusalem



**Prof. Nissim Garti**  
Hebrew University of  
Jerusalem, Israel



**Prof. Anat Loewenstein**  
Tel Aviv medical  
center, Israel



**Prof. Ike Ahmed**  
John A. Moran Eye  
Center, Utah, US



**Prof. Jeff Goldberg**  
Byers Eye Institute at  
Stanford University,  
California, US



**Prof. Avi Domb**  
Hebrew University of  
Jerusalem, Israel




**Susan Benton**  
President and BoD,  
multiple ophthalmology  
companies



**Dr. Vicente Anido**  
Previous BoD and CEO,  
multiple ophthalmology  
companies

# Roadmap





**Thank you.**

**Yaacov Michlin** | BioLight CEO; OCUVIA Chairman

Yaacov@bio-light.co.il